These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].
    Author: Lu W, Lu WQ.
    Journal: Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):309-12. PubMed ID: 22454182.
    Abstract:
    Gastrointestinal stromal tumor(GIST) originates from interstitial cells of Cajal(ICCs). Tyrosine kinase inhibitors(TKI) such as imatinib and sunitinib, are effective agents besides surgery. However some GIST can become primarily or secondarily resistant to those drugs. The difference in gene mutation types and secondary gene mutation is the main cause. When the GIST is proved to be drug resistance, reasonable personal treatment strategies based on individualized medicine should be made to improve outcomes and quality of life.
    [Abstract] [Full Text] [Related] [New Search]